from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. The active metabolite of leflunomide.


Sorry, no etymologies found.


  • Separately, French drug maker Sanofi SA said a drug it is developing for multiple sclerosis, teriflunomide, failed to prove more effective than an older MS drug in a trial in 324 patients.

    AstraZeneca, Novartis Report Drug Setbacks

  • The study showed teriflunomide also reduced disability progression by 30% and 24%, depending on the dose, Sanofi said.

    Sanofi Says MS Drug Reduces Relapses

  • PARIS — French pharmaceutical giant Sanofi-Aventis said Friday a two-year phase III study of its multiple-sclerosis drug teriflunomide reduced the relapse rate of patients by 31%.

    Sanofi Says MS Drug Reduces Relapses

  • Recent data from large clinical trials of other drugs being developed, including Biogen Idec's BG-12, Teva Pharmaceutical's laquinimod, and teriflunomide, from Sanofi-Aventis SA, show they are also effective at controlling MS flare-ups and slowing the progression of disability from the disease.

    Pills Offer Easier Way to Treat MS

  • Smaller reductions in flare-ups were seen in trials with patients using laquinimod (23%) and teriflunomide (31%).

    Pills Offer Easier Way to Treat MS

  • France's Sanofi-Aventis SA, meanwhile, is carrying out large clinical trials of an oral MS drug called teriflunomide.

    Novartis's MS Drug Wins U.S. Approval

  • Sanofi said teriflunomide, also known by the trade name Aubagio, worked no better than an older drug, Rebif, in preventing relapses, as the study found "no statistical superiority" between Rebif and either 7 mg or 14 mg doses of teriflunomide.

    The Seattle Times

  • French drugmaker Sanofi says its multiple sclerosis drug candidate teriflunomide did not achieve one of its goals in a late-stage clinical trial.

    The Seattle Times

  • The monotherapy program of teriflunomide progress as planned with the two Phase III trials ongoing, TOWER (versus placebo) and TENERE (versus IFN-beta 1a).

  • Throughout 2011, further newsflow from R&D is expected with Phase III studies expected to be completed/reported for five compounds currently in development lixisenatide, teriflunomide, aflibercept, ombrabulin, and semuloparin.


Log in or sign up to get involved in the conversation. It's quick and easy.